Tradestie Institutional Equity Comparison Engine

CRSP vs LGND โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LGND Overall Edge

LGND Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ligand Pharmaceuticals Inc. (LGND) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus LGND at 25.8x Forward P/E and 14.4% operating margin (-31.8% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against LGND sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs LGND 25.8x Fwd P/E
Growth & Margin Winner LGND
Op Margin -2058.6% vs 14.4% ยท YoY +1325.1% vs -31.8%
Momentum & Technical Winner LGND
1Y -20.5% vs +51.5% ยท 52W Pos 1% vs 86%
Options & Structure Winner LGND
BREAKDOWN (52nd %ile IV) vs CONSOLIDATION (8th %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
LGND NASDAQ
Ligand Pharmaceuticals Inc.
Pharmaceutical Preparations
$304.93
-1.25% 1D
Market Cap $6.3B
1M Return +3.18%
1Y Return +51.5%
Forward P/E 25.8x
Unified AI Score
42.9 / 100 HOLD
Tech 45.0 Fund 47.0 Flow 63.0 Mom 31.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% LGND +51.5% Spread: +72.04 pp (LGND Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue LGND Revenue CRSP Op. Margin LGND Op. Margin Margin Edge
FY2018 $0M $250M -5087.8% 65.1% LGND
FY2019 $290M $120M 16.1% 671.0% LGND
FY2020 $0M $160M -49295.5% 22.9% LGND
FY2021 $910M $240M 40.8% 43.0% LGND
FY2022 $0M $200M -56190.4% 1.5% LGND
FY2023 $370M $130M -60.0% 9.1% LGND
FY2024 $40M $170M -1250.4% -13.5% LGND
FY2025 $0M $270M -18933.6% 15.3% LGND

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (4) vs LGND (6)
Institutional Metric CRSP LGND Criterion Row Winner
Market Capitalization Scale $4.1B $6.3B Larger Scale LGND
Trailing P/E Ratio Valuation 23.4x 127.0x Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x 25.8x Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% -31.8% Higher Growth CRSP
Operating Margin (TTM) Profitability -2058.6% 14.4% Higher Margin LGND
Net Profit Margin Profitability 0.0% 20.3% Higher Margin LGND
Return on Equity (ROE) Capital Efficiency -25.6% 5.4% Higher ROE LGND
52-Week Range Position Momentum 1% ($40โ€“$63) 86% ($176โ€“$327) Stronger Trend LGND
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 0.99ฮฒ ยท 38% Vol Lower Realized Risk LGND
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs LGND Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LGND CONSOLIDATION
98d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live LGND Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor LGND registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.